About the Fund

The Life Sciences Growth Fund will invest in companies at the forefront of the sector, with a focus toward UK and European small to mid-cap opportunities that are often underfunded or overlooked. We target businesses with mid to late-stage development programmes and meaningful prior clinical investment, management depth and the intellectual property needed to support commercial success, focusing capital on areas of significant unmet medical need.

 

Investment selection and ongoing portfolio oversight will be led by an expert committee of clinicians, life sciences industry and investment specialists, applying disciplined diligence and governance with clear performance, clinical and development milestones.

 

A key differentiator is LGC’s ability to support portfolio companies directly through efficient trial design and regulatory pathway optimisation, helping accelerate progress toward value-creating inflection points.

​

The Fund will invest across a portfolio of private and listed securities, with the objective of stewarding approximately eight to ten core private companies through clinical milestones to strategic outcomes, aiming to drive meaningful health impact alongside attractive investor returns.

 

The Fund will give institutional investors access to both listed and private equity healthcare investments through regulated and governed LTAF structures.